{"classes":[{"categories":[{"measurements":[{"comment":"Not reached","groupId":"OG000","lowerLimit":"37","upperLimit":"NA","value":"47.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"Duration of response is defined as the time from objective response to disease progression or death, or date last known progression-free and alive for those who have not progressed or died","dispersionType":"95% Confidence Interval","groups":[{"description":"* Cycles 1-9\n\n  * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle\n  * Lenalidomide is administered orally on days 1-21 on a 28 days cycle\n  * Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle\n* Cycle 10-24\n\n  * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle\n  * Lenalidomide is administered orally on days 1-21 on a 28 days cycle\n* Supportive measures consistent with optimal patient care may be given throughout the study\n\nIxazomib: Oral, proteasome inhibitor\n\nLenalidomide: Oral, immunomodulatory agent\n\nDexamethasone: Oral, steroid","id":"OG000","title":"Ixazomib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"time from objective response to disease progression or death, or date last known progression-free and alive for those who have not progressed or died, or up to 60 months post initiation of therapy","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}